The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,566,717 in first-year total cost, median $2,467,399.
Most frequent study sections
- Special Emphasis Panel[ZDA1 JXR-D (04)]1
- Special Emphasis Panel[ZDA1 JXR-D (05)]1
- Special Emphasis Panel[ZDA1 JXR-D (08)]1
- Special Emphasis Panel[ZDA1 JXR-D (10)]1
- Special Emphasis Panel[ZDA1 JXR-D (15)]1
Most frequent institutions
- EMBERA NEUROTHERAPEUTICS, INC.1
- HENNEPIN HEALTHCARE RESEARCH INSTITUTE1
- INTERVEXION THERAPEUTICS, LLC1
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE1
- UNIVERSITY OF CINCINNATI1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Preclinical studies for the development of selective mGlu2 positive allosteric modulators to treat substance use disorders1U01DA041731-01A1 | COSFORD, NICHOLAS DAVID | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $2,646,217 | ZDA1 |
| 2016 | EMB-001: A novel combination therapy for the treatment of cocaine-use disorder1U01DA038879-01A1 | DETKE, MICHAEL J. | EMBERA NEUROTHERAPEUTICS, INC., MA | $4,057,614 | ZDA1 |
| 2015 | Vaccines for prescription opioid and heroin abuse1U01DA038876-01A1 | PENTEL, PAUL RPRAVETONI, MARCO | HENNEPIN HEALTHCARE RESEARCH INSTITUTE, MN | $2,467,399 | ZDA1 |
| 2015 | Advancing the Development of a Humanized Anti-cocaine Monoclonal Antibody1U01DA039550-01 | NORMAN, ANDREW B | UNIVERSITY OF CINCINNATI, OH | $2,108,009 | ZDA1 |
| 2014 | Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb1U01DA037593-01A1 | GENTRY, W BROOKSSTEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $1,287,478 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.